Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Monopar Therapeutics stock

Own Monopar Therapeutics stock in just a few minutes.

Fact checked

Monopar Therapeutics Inc is a biotechnology business based in the US. Monopar Therapeutics shares (MNPR) are listed on the NASDAQ and all prices are listed in US Dollars. Monopar Therapeutics employs 6 staff and has a market cap (total outstanding shares value) of USD$84.2 million.

How to buy shares in Monopar Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Monopar Therapeutics. Find the stock by name or ticker symbol: MNPR. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Monopar Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Monopar Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Monopar Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Monopar Therapeutics share price

Use our graph to track the performance of MNPR stocks over time.

Monopar Therapeutics shares at a glance

Information last updated 2021-02-23.
52-week rangeUSD$4.28 - USD$10.55
50-day moving average USD$7.6152
200-day moving average USD$5.9165
Wall St. target priceUSD$35
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-0.4054

Buy Monopar Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Robinhood
$0
Stocks, Options, ETFs, Gold/Commodities
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
$0
Stocks, Bonds, Options
$0 + $0.65/contract, $1 minimum
0%
N/A
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Tastyworks
$0
Stocks, Options, Cryptocurrency
Stocks & ETFs: $1/contract to open, $0 to close, $10 max/leg
Futures: $2.50/contract to open, $0 to close
0%
Get 100 shares of stock (worth $1 to $6 a share)
Open and fund a new cash or margin account with $2,000+
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
TradeStation
$0
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$50
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Monopar Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Monopar Therapeutics financials

Gross profit TTM USD$0
Return on assets TTM -29.41%
Return on equity TTM -48.68%
Profit margin 0%
Book value $0.498
Market capitalisation USD$84.2 million

TTM: trailing 12 months

Shorting Monopar Therapeutics shares

There are currently 23,595 Monopar Therapeutics shares held short by investors – that's known as Monopar Therapeutics's "short interest". This figure is 1.8% down from 24,031 last month.

There are a few different ways that this level of interest in shorting Monopar Therapeutics shares can be evaluated.

Monopar Therapeutics's "short interest ratio" (SIR)

Monopar Therapeutics's "short interest ratio" (SIR) is the quantity of Monopar Therapeutics shares currently shorted divided by the average quantity of Monopar Therapeutics shares traded daily (recently around 138794.11764706). Monopar Therapeutics's SIR currently stands at 0.17. In other words for every 100,000 Monopar Therapeutics shares traded daily on the market, roughly 170 shares are currently held short.

However Monopar Therapeutics's short interest can also be evaluated against the total number of Monopar Therapeutics shares, or, against the total number of tradable Monopar Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Monopar Therapeutics's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Monopar Therapeutics shares in existence, roughly 0 shares are currently held short) or 0.0073% of the tradable shares (for every 100,000 tradable Monopar Therapeutics shares, roughly 7 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Monopar Therapeutics.

Find out more about how you can short Monopar Therapeutics stock.

Monopar Therapeutics share dividends

We're not expecting Monopar Therapeutics to pay a dividend over the next 12 months.

Monopar Therapeutics overview

Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site